Axsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at …

1 day ago · 5 medical stocks growing earnings by triple digits; Other equities research analysts have also issued research reports about the stock. Robert W. Baird boosted their price …

$125.00
OFF

Axsome Therapeutics (AXSM) Gets A Buy From TD Cowen

2 weeks from now

1 day ago · In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $125.00. The …

businessinsider.com

$121.00
OFF

Axsome Therapeutics (NASDAQ:AXSM) Earns "Buy" Rating From …

2 weeks from now

Jan 6, 2025 · Cantor Fitzgerald reiterated an "overweight" rating and set a $121.00 price target on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Robert W. …

marketbeat.com

$180
OFF

Truist Raises Axsome Stock Target To $180, Maintains Buy Rating

2 weeks from now

5 days ago · The firm sustained a Buy rating on the shares, signaling confidence in the biopharmaceutical company's prospects. ... analysts maintain a strong buy consensus with …

investing.com

$133.00
OFF

What Is Zacks Research’s Estimate For AXSM FY2024 Earnings?

2 weeks from now

4 days ago · A number of other brokerages have also issued reports on AXSM. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price target on shares of Axsome …

etfdailynews.com

5%
OFF

Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?

2 weeks from now

Axsome Therapeutics (AXSM) shares ended the last trading session 11.5% higher at $89.27. The jump came on an impressive volume with a higher-than-average number of shares changing …

nasdaq.com

90%
OFF

Axsome AXS-05 ADA Results Supportive Of Approval, Says BofA

2 weeks from now

Dec 30, 2024 · The firm, which sees today’s trial outcome scenario as supportive of ADA approval, makes no change to its 90% odds of success estimate nor its Buy rating and $118 …

nasdaq.com

100%
OFF

This Stock Crushed The Market Last Year. Here's Why It Could

2 weeks from now

Jun 16, 2023 · Axsome Therapeutics (NASDAQ: AXSM) started out last year as a small up-and-coming biotech company. It finished the year with a more than 100% gain, beating the bear …

nasdaq.com

$121.00
OFF

Truist Financial Forecasts Strong Price Appreciation For Axsome ...

2 weeks from now

2 days ago · Cantor Fitzgerald reiterated an "overweight" rating and set a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday, December 12th. Finally, Mizuho …

marketbeat.com

$116.42
OFF

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

2 weeks from now

19 analysts have given Axsome Therapeutics (AXSM) a consensus rating of Buy while the Axsome Therapeutics (AXSM) price prediction in 2025 is $116.42 ... depressive disorder …

public.com

$100
OFF

ServiceTitan Stock Tanks Despite Strong Q3, Analysts ... - Benzinga

2 weeks from now

20 hours ago · Goldman Sachs analyst Kash Rangan reiterated a Neutral rating, while raising the price target from $100 to $108. Needham analyst Scott Berg reaffirmed a Buy rating and price …

benzinga.com

$155
OFF

Top Wall Street Analysts Like The Growth Opportunities For These

2 weeks from now

On Jan. 6, Monness analyst Brian White reiterated a buy rating on Datadog stock with a price target of $155. The analyst thinks that the company has a more balanced approach toward the …

msn.com

5%
OFF

Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?

2 weeks from now

1 day ago · Axsome Therapeutics (AXSM Quick Quote AXSM - Free Report) shares ended the last trading session 11.5% higher at $89.27. The jump came on an impressive volume with a …

zacks.com

$1.34
OFF

Research Analysts Set Expectations For AXSM FY2024 Earnings

2 weeks from now

6 days ago · Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th.The company reported ($1.34) earnings per …

marketbeat.com

FAQs about Axsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at … Coupon?

Is Axsome Therapeutics (axsm) a good stock to buy?

Axsome Therapeutics ( AXSM -1.51%) wowed investors late last year with strong data from a phase 3 study of AXS-05, its candidate treatment for Alzheimer's disease agitation. AXS-05 met its primary and secondary goals in the study, and importantly, looked to be on track to enter the market with zero competition. ...

How do I receive news & ratings for Axsome Therapeutics?

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

Who is Axsome Therapeutics?

(Get Free Report) Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. ...

Is Thome a good stock to buy?

According to TipRanks, Thome is an analyst with an average return of -5.0% and a 37.95% success rate. Thome covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, PTC Therapeutics, and Axsome Therapeutics. ...

Does FMR LLC own Axsome Therapeutics?

FMR LLC boosted its holdings in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 2.7% in the third quarter. ...

Is Axsome the same as auvelity?

The same is likely true for Axsome's candidate. But, in both cases, these drugs also treat other conditions. Axsome won regulatory approval for AXS-05 last year for use in major depressive disorder. As a commercialized drug, it's now called Auvelity. ...